Trial · NCT05804084
Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea
NCT05804084, Phase 2, Recruiting, University of California, San Diego
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea. Trials, record NCT05804084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05804084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea
- NCT number
- NCT05804084
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of California, San Diego
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Acetazolamide, Placebo
- First posted
- 2023-04-07
- Last updated
- 2026-05-08
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Apnea Hypopnea Index (AHI) | 4 weeks | The AHI is a measure of sleep apnea severity and is defined as the number of apneas (no breathing for 10+ seconds) and hypopneas (reduced breathing for 10+ seconds associated with a \>=3% desaturation or cortical arousal) per hour of sleep. Alternative definitions of the AHI will be explored as well (e.g. hypopneas based on 4% desaturations, or position/sleep-stage specific AHIs). |
| Secondary | Hypoxic Burden (percent*minute/hour) | 4 weeks | Respiratory event-associated area under the desaturation curve from pre-event baseline (continuous outcome with units being "percent\*minutes/hour") |
| Secondary | Overnight Memory Improvement (change in percentage points) | 4 weeks | Based on Verbal Paired-Associates task |
| Secondary | Cognitive function composite score | 4 weeks | Total composite score from the National Institutes of Health (NIH) Toolbox based on 7 cognitive domains which will also be explored separately and via subscales (i.e., (Fluid and Crystaliized Cognition Composite Scores). These scores are based on a T-Score metric, with a normative mean of 50 and an SD of 10. Higher scores indicate better cognitive function. |
| Secondary | Response Speed | 4 weeks | 10-minute Psychomotor vigilance task (PVT) |
| Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SDA) instrument | 4 weeks | Based on response pattern scoring, the PROMIS 8-item SDA score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep disturbance. |
| Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment (SRI) instrument | 4 weeks | Based on response pattern scoring, the PROMIS 8-item SRI score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment. |
| Secondary | Epworth Sleepiness Scale (ESS) Score | 4 weeks | The ESS is an 8-item instrument assessing the likelihood of dozing off in 8 different situations with points for each item ranging from 0 to 3 (0 = would never doze off; 3 = high chance of dozing off). The points for each item are summed up, thus the total score ranges from 0 to 24, with higher ESS scores indicating greater sleepiness. |
| Secondary | Functional Outcomes of Sleep Questionnaire 10 (FOSQ-10) | 4 weeks | The FOSQ-10 is a 10-item instrument assessing sleep-related quality of life across 5 domains (general productivity, activity level, vigilance, social outcomes, intimacy and sexual relationships). Each item is scored on a scale ranging from 1 to 4 (a higher number indicates a better functional status for that item). The mean scores of the 5 subscales are averaged and then multiplied by 5 to calculate a total summary score ranging from 5-20 (higher scores indicate better functional outcomes). The main focus will be on the total summary score, but scores from subscales will be explored as well. |
| Secondary | Short Form 36 (SF-36) Health Survey | 4 weeks | The SF36 is a widely used questionnaire to measure general health-related quality of life across 8 domains (e.g. physical functioning, Energy/fatigue, Social functioning, etc). The score for each of the 8 domains ranges from 0 to 100, with greater scores indicating better health-related quality fo life in this domain. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL161336 | Acetazolamide to Improve Clinically Important Outcomes in Obstructive Sleep Apnea Patients with a High Loop Gain Endotype | SCHMICKL, CHRISTOPHER NIKOLAUS | UNIVERSITY OF CALIFORNIA, SAN DIEGO | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Psychomotor Vigilance Task | Secondary outcome | ConductCognition |
| Word Pair Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05804084
GET https://conductscience.org/api/trials/v1/NCT05804084/registered